Results 251 to 260 of about 171,164 (312)

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Speech-Language Pathology. Editorial.

open access: yesJornal da Sociedade Brasileira de Fonoaudiologia, 2012
openaire   +1 more source

Recurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up

open access: yes
American Journal of Hematology, EarlyView.
Jennifer A. Woyach   +16 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Current and prospective speech-language pathology students' reports of exposure to speech-language pathology

International Journal of Speech-Language Pathology, 2008
This paper presents findings of an investigation into the amount of exposure to the speech-language pathology profession that is reported by current and prospective speech-language pathology students. This study investigated both therapeutic and social exposures to speech-language pathology (SLP) as both were considered to play a role in providing ...
Nicole Byrne
exaly   +3 more sources

Home - About - Disclaimer - Privacy